The supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program

Cambridge, UK, 10 April 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, today announces the supply of its HQ synthetic DNA to a Tier 1 Pharma Company. Following successful completion of an opDNA™ evaluation study, our client has now progressed to HQ opDNA™ for late preclinical studies for an mRNA vaccine program. Supply of GMP grade material for clinical trials is anticipated in Q3.

Dr Heikki Lanckriet, CEO at the Company, commented: "This is a major achievement for our company and is significant both in terms of product quantity and value. It’s a clear recognition of the strengths of our synthetic DNA products, our product quality, and our manufacturing capabilities.

“There is strong interest in our synthetic DNA products, and we are now supporting a growing number of projects into the clinic. We expect client acquisition and revenue generation to continue accelerating as our expanding client base progress their clinical programs.”